Leo Pharma expects new FDA ruling for eczema treatment tralokinumab in early 2022
After receiving a complete response letter from the FDA in Spring 2021, Leo Pharma is hoping for a positive result in the first quarter of next year after submitting extra data.
by elizabeth mønsted johansen, translated by catherine brett
As Leo Pharma rolls out eczema treatment tralokinumab in Europe under the name of Adtralza, it is waiting for a new ruling on the same drug in the US, where it was denied marketing approval last year.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
